Xin V. Wang

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Xin V. Wang, Neil E. Kay et al. · New England Journal of Medicine · 2019 · 738 citations · Full text

Medicine, Immunology, Oncology +16

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

Mark R. Litzow, Xin V. Wang, Martin Carroll et al. · American Journal of Hematology · 2018 · 27 citations · Full text

Medicine, Oncology, Pharmacology +14

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

Richard D. Gelber, Xin V. Wang, Bernard F. Cole et al. · European Journal of Cancer · 2022 · 19 citations · Full text

Medicine, Biostatistics, Oncology +17

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Chezi Ganzel, Xin V. Wang, Jacob M. Rowe et al. · British Journal of Haematology · 2020 · 17 citations · Full text

Medicine, Oncology, Cancer Control +12